Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib

Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment for patients with CD19(+) B-cell malignancies. Combination strategies that improve CAR T-cell potency, limit tumor environment–mediated immune dysfunction, and directly reduce tumor burden may increase the potential for durable...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Jim S., Johnstone, Timothy G., Baturevych, Alex, Hause, Ronald J., Ragan, Seamus P., Clouser, Christopher R., Jones, Jon C., Ponce, Rafael, Krejsa, Cecile M., Salmon, Ruth A., Ports, Michael O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Basic Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144752/
https://www.ncbi.nlm.nih.gov/pubmed/31899702
http://dx.doi.org/10.1097/CJI.0000000000000307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144752/
https://www.ncbi.nlm.nih.gov/pubmed/31899702
http://dx.doi.org/10.1097/CJI.0000000000000307

Ejemplares similares